Manufacturer of Controlled Substances; Notice of Application, 46231-46232 [E9-21522]

Download as PDF 46231 Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices Drug Schedule jlentini on DSKJ8SOYB1PROD with NOTICES Tilidine (9750) ............................... Trimeperidine (9646) .................... 1-Phenylcyclohexylamine (7460) 1Piperidinocyclohexanecarbonitrile (8603). Alfentanil (9737) ........................... Alphaprodine (9010) ..................... Amobarbital (2125) ....................... Amphetamine (1100) .................... Anileridine (9020) ......................... Bezitramide (9800) ....................... Carfentanil (9743) ......................... Coca Leaves (9040) ..................... Cocaine (9041) ............................. Codeine (9050) ............................. Dextropropoxyphene, bulk (nondosage forms) (9273). Dihydrocodeine (9120) ................. Dihydroetorphine (9334) ............... Diphenoxylate (9170) ................... Ethylmorphine (9190) ................... Etorphine Hcl (9059) .................... Fentanyl (9801) ............................ Glutethimide (2550) ...................... Hydrocodone (9193) ..................... Hydromorphone (9150) ................ Isomethadone (9226) ................... Levo-alphacetylmethadol (9648) .. Levomethorphan (9210) ............... Levorphanol (9220) ...................... Lisdexamfetamine (1205) ............. Meperidine (9230) ........................ Meperidine intermediate-A (9232) Meperidine intermediate-B (9233) Meperidine intermediate-C (9234) Metazocine (9240) ........................ Methadone (9250) ........................ Methadone intermediate (9254) ... Methamphetamine (1105) ............ Methylphenidate (1724) ................ Metopon (9260) ............................ Moramide intermediate (9802) ..... Morphine (9300) ........................... Nabilone (7379) ............................ Opium, raw (9600) ....................... Opium extracts (9610) .................. Opium fluid extract (9620) ............ Opium tincture (9630) .................. Opium, granulated (9640) ............ Oxycodone (9143) ........................ Oxymorphone (9652) ................... Pentobarbital (2270) ..................... Phenazocine (9715) ..................... Phencyclidine (7471) .................... Phenmetrazine (1631) .................. Phenylacetone (8501) .................. Piminodine (9730) ........................ Powdered opium (9639) ............... Racemethorphan (9732) .............. Racemorphan (9733) ................... Remifentanil (9739) ...................... Secobarbital (2315) ...................... Sufentanil (9740) .......................... Thebaine (9333) ........................... I I II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II Dated: August 28, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–21534 Filed 9–4–09; 8:45 am] BILLING CODE 4410–09–M DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application The company plans to import small quantities of the listed controlled substances for the National Institute on Drug Abuse (NIDA) for research activities. No comments or objections have been received. DEA has considered the VerDate Nov<24>2008 17:32 Sep 04, 2009 Jkt 217001 factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Research Triangle Institute to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Research Triangle Institute to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 21, 2009, Chemic Laboratories, Inc., 480 Neponset Street, Building 7, Canton, Massachusetts 02021, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in schedule II. The company plans to manufacture small quantities of the above listed controlled substance for distribution to its customers for the purpose of research. Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, PO 00000 Frm 00152 Fmt 4703 Sfmt 4703 Springfield, Virginia 22152; and must be filed no later than November 9, 2009. Dated: August 28, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–21521 Filed 9–4–09; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 8, 2009, Cody Laboratories, 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Dihydromorphine (9145) ............... Amphetamine (1100) .................... Methamphetamine (1105) ............ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Phenylacetone (8501) .................. Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Diphenoxylate (9170) ................... Ecgonine (9180) ........................... Hydrocodone (9193) ..................... Meperidine (9230) ........................ Methadone (9250) ........................ Morphine (9300) ........................... Oxymorphone (9652) ................... Alfentanil (9737) ........................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ Schedule I II II II II II II II II II II II II II II II II II II II II II II The company plans on manufacturing the listed controlled substances in bulk for sale to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than November 9, 2009. E:\FR\FM\08SEN1.SGM 08SEN1 46232 Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices Dated: August 28, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–21522 Filed 9–4–09; 8:45 am] 27709, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug BILLING CODE 4410–09–P Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Cocaine (9041) ............................. DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 26, 2009, Noramco Inc., Division of OrthoMcNeil, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801–4417, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of Noroxymorphone (9668), a basic class of controlled substance listed in schedule II. The company plans to bulk manufacture the listed controlled substance as a reference standard for distribution to its customers which are analytical laboratories. Any other such applicant, and any person who is presently registered with DEA to manufacture such a substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, VA 22152; and must be filed no later than November 9, 2009. Dated: August 28, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–21524 Filed 9–4–09; 8:45 am] DEPARTMENT OF JUSTICE The Institute will manufacture small quantities of cocaine and marihuana derivatives for use by their customers in analytical kits, reagents, and reference standards as directed by the National Institute on Drug Abuse. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than November 9, 2009. Dated: August 21, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–21526 Filed 9–4–09; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Drug Enforcement Administration Drug jlentini on DSKJ8SOYB1PROD with NOTICES Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 18, 2009, Research Triangle Institute, Kenneth H. Davis Jr., Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle, North Carolina 17:32 Sep 04, 2009 Jkt 217001 I I II Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 1, 2009, Alltech Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: BILLING CODE 4410–09–P VerDate Nov<24>2008 Schedule Schedule Methcathinone (1237) .................. N-Ethylamphetamine (1475) ........ N,N-Dimethylamphetamine (1480) 4-Methylaminorex (cis isomer) (1590). Alpha-ethyltryptamine (7249) ....... Lysergic acid diethylamide (7315) 2,5-Dimethoxy-4-(n)propylthiophenethylamine (7348). PO 00000 Frm 00153 Fmt 4703 Sfmt 4703 I I I I I I I Drug Tetrahydrocannabinols (7370) ..... Mescaline (7381) .......................... 4-Bromo-2,5dimethoxyamphetamine (7391). 4-Bromo-2,5dimethoxyphenethylamine (7392). 4-Methyl-2,5dimethoxyamphetamine (7395). 2,5-Dimethoxyamphetamine (7396). 2,5-Dimethoxy-4ethylamphetamine (7399). 3,4-Methylenedioxyamphetamine (7400). N-Hydroxy-3,4methylenedioxyamphetamine (7402). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4Methylenedioxymethamphetamine (MDMA) (7405). 4-Methoxyamphetamine (7411) ... Alpha-methyltryptamine (7432) .... Bufotenine (7433) ......................... Diethyltryptamine (7434) .............. Dimethyltryptamine (7435) ........... Psilocybin (7437) .......................... Psilocyn (7438) ............................. 5-Methoxy-N,Ndiisopropyltryptamine (7439). N-Ethyl-1-phenylcyclohexylamine (7455). 1-(1-Phenylcyclohexyl)pyrrolidine (7458). 1-Phenylcyclohexylamine (7460) 1-[1-(2Thienyl)cyclohexyl]piperidine (7470). Normorphine (9313) ..................... Methamphetamine (1105) ............ Phencyclidine (7471) .................... Phenylacetone (8501) .................. 1Piperidinocyclohexanecarbonitrile (8603). Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Dihydromorphine (9145) ............... Ecgonine (9180) ........................... Meperidine intermediate-B (9233) Noroxymorphone (9668) .............. Schedule I I I I I I I I I I I I I I I I I I I I I I I I II II II II II II II II II II II The company plans to manufacture high purity drug standards used for analytical application only in clinical, toxicological, and forensic laboratories. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, E:\FR\FM\08SEN1.SGM 08SEN1

Agencies

[Federal Register Volume 74, Number 172 (Tuesday, September 8, 2009)]
[Notices]
[Pages 46231-46232]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-21522]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on July 8, 2009, Cody 
Laboratories, 601 Yellowstone Avenue, Cody, Wyoming 82414, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of the basic classes of controlled 
substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Dihydromorphine (9145).....................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Amobarbital (2125).........................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Phenylacetone (8501).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Diphenoxylate (9170).......................  II
Ecgonine (9180)............................  II
Hydrocodone (9193).........................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Morphine (9300)............................  II
Oxymorphone (9652).........................  II
Alfentanil (9737)..........................  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans on manufacturing the listed controlled substances 
in bulk for sale to its customers.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than November 9, 2009.


[[Page 46232]]


    Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-21522 Filed 9-4-09; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.